Download PDF
Thromb Haemost 1979; 42(03): 929-944
DOI: 10.1055/s-0038-1656983
Original Article
Schattauer GmbH Stuttgart

In Vitro Effect of p-Chlormercuribenzoate upon Dilute Blood Clot Lysis Time in Hyperlipemia

Mircea P Cucuianu
The Medical Clinic No. 1, Cluj-Napoca, Romania
,
Codruta Stef
The Medical Clinic No. 1, Cluj-Napoca, Romania
,
Dorel Zdrenghea
The Medical Clinic No. 1, Cluj-Napoca, Romania
,
Octavian Popescu
The Medical Clinic No. 1, Cluj-Napoca, Romania
› Author Affiliations
Further Information

Publication History

Received 12 July 1978

Accepted 20 November 1978

Publication Date:
23 August 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In comparison to values obtained in normal-weight normolipenic controls, dilute blood clot lysis time was found to be prolonged in resting and exercised patients with endogenous hypertriglyceridemia. Lysis time was also prolonged in overweight subjects with only slightly increased serum lipids but it was not significantly changed in type II-a hyperlipoproteinemia. An obvious acceleration of clot lysis was noted in patients with decompensated cirrhosis of the liver. Inclusion of p-chlormercuribenzoate (PCMB) into the diluted blood clot caused an acceleration of lysis time. This effect was particularly obvious with hypertriglyceridemic blood and minimal with blood obtained from cirrhotic patients. Addition of various amounts of heat-defibrinated plasma to blood from cirrhotic patients caused a proportional prolongation of clot lysis time and this effect was greatly diminished in the presence of PCMB. Similar amounts of serum had a much lesser effect than defibrinated plasma. Inhibition of fibrin cross-linking by PCMB was confirmed by sodium dodecylsulfate polyacrylamide gel electrophoresis.

The present data complete previous observations concerning a higher plasma factor XIII activity in type II-b and type IV hyperlipoproteinemia and suggest that an increased crosslinking of fibrin might partially explain the deficient thrombolysis of hypertriglyceridemic patients.

 

  • References

  • 1 Almér LO, Nilsson IM. 1975; On fibrinolysis in diabetes mellitus. Acta medica Scandinavica 198: 101
    PubMedGoogle Scholar
  • 2 Aoki N, Yamanaka T. 1978; The α2 plasmin inhibitor levels in liver disease. Clinica Chimica Acta 84: 99
    CrossrefPubMedGoogle Scholar
  • 3 Astrup P, Brakman P, Nissen U. 1965; The estimation of fibrinogen. A revision. Scandinavian Journal of Clinical Laboratory Investigation 17: 57
    CrossrefPubMedGoogle Scholar
  • 4 Brakman P, Astrup T, Levy RI, Fredrickson DS. 1974; Resting levels of blood fibrinolysis in hyperlipoproteinemia. Journal of Applied Physiology 36: 430
    CrossrefPubMedGoogle Scholar
  • 5 Cucuianu M. 1966; Betalipoproteins and Euglobulin lysis time. Thrombosis et Diathesis Haemor- rhagica 16: 687
    PubMedGoogle Scholar
  • 6 Cucuianu M, Popescu TA, Haragus S. 1972; Clinical studies concerning inhibition of fibrinolysis in a urokinase activated system - with special reference to atherosclerosis and the proteosynthetic function of the liver. Revue Roumaine de Medicine Interne (Bucharest) 9: 377
    PubMedGoogle Scholar
  • 7 Cucuianu M, Vasile V, Popescu TA, Opincaru A, Crisnic I, Tapalaga D. 1973; Clinical studies concerning factor XIII; with special reference to hyperlipemia. Thrombosis et Diathesis Haemorrhagica 30: 480
    PubMedGoogle Scholar
  • 8 Cucuianu M, Miloszewski K, Porutiu D, Losowsky MS. 1976; Plasma factor XIII and platelet factor XIII in hyperlipaemia. Thrombosis and Haemostasis 36: 542
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 De La Huerga J, Yesinick C, Popper H. 1952; Colorimetric method for the determination of serum cholinesterase. American Journal of Clinical Pathology 22: 1126
    CrossrefPubMedGoogle Scholar
  • 10 Epstein ES, Rosing DR, Brakman P, Redwood DR, Astrup T. 1970; Impaired fibrinolytic response to exercise in patients with type IV hyperlipoproteinemia. Lancet 2: 631
    PubMedGoogle Scholar
  • 11 Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S. 1964; Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. Journal of Clinical Investigation 43: 681
    CrossrefPubMedGoogle Scholar
  • 12 Gallimore MJ, Shaw JT B. 1969; The influence of various plasma components on the lysis of dilute human blood clots Thrombosis et Diathesis. Haemorrhagic 22: 223
    PubMedGoogle Scholar
  • 13 Gallimore MJ, Tyler HM, Shaw JT B. 1971; The measurement of fibrinolysis in the rat. Thrombosis et Diathesis Haemorrhagica 26: 295
    PubMedGoogle Scholar
  • 14 Korsan-Bengsten K. 1972. Risk factors in the pathogenesis of thrombosis. In Brinkhous KM, Owren PA, Hinnom S, Surgenor DM, Sherry S, Stengle JM. (Eds.) Thrombosis- Risk Factors and Diagnostic Aproaches. Transactions of the second Congress held under the Auspices of the International Society on Thrombosis and Haemostasis and of the International Committee on Haemostasis and Thrombosis, Oslo, July 12 to 16, 1971. Schattauer Stuttgart; New York: p 199
    Google Scholar
  • 15 Laemmli UK. 1970; Cleavage of structural proteins during assembly of the head of the bacteriophage T 4. Nature 227: 680
    CrossrefPubMedGoogle Scholar
  • 16 Lamb RG, Fallon AJ. 1972; An enzymatic explanation for increased hepatic triglyceride formation in rats fed high sugar diets. Journal of Clinical Investigations 51 abstract 173, p 53 a
    PubMedGoogle Scholar
  • 17 Langer T, Strober W, Levy RJ. 1972; The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. Journal of Clinical Investigation 51: 1528
    CrossrefPubMedGoogle Scholar
  • 18 Lorand L, Jacobsen A. 1962; Accelerated lysis of blood clots. Nature 195: 911
    PubMedGoogle Scholar
  • 19 Lorand JG, Pilkington RE, Lorand L. 1966; Inhibitors of fibrin cross-linking: relevance for thrombolysis. Nature 210: 1273
    CrossrefPubMedGoogle Scholar
  • 20 Maki M, Beller FK. 1966; Comparative studies of fibrinolytic inhibitors in vitro. Thrombosis et Diathesis Haemorrhagica 16: 668
    PubMedGoogle Scholar
  • 21 Martin PJ, Martin JV, Goldberg DM. 1975; Gamma-glutamyl transpeptidase, triglycerides and enzyme induction. British Medical Journal 1: 17
    CrossrefPubMedGoogle Scholar
  • 22 Mckee PA, Schwartz ML, Pizzo SV, Hill RL. 1972; Cross-linking of fibrin by fibrin- stabilizing factor. Annals of the New York Academy of Sciences 202: 127
    CrossrefPubMedGoogle Scholar
  • 23 Nanninga LB, Guest MM. 1965; Blocking of inhibition of fibrinolysis by mercurials and oxidising agents. Archives of Biochemistry 109: 607
    CrossrefPubMedGoogle Scholar
  • 24 Nestel PJ, Whyte HM. 1968; Plasma free fatty acid and triglyceride turnover in obesity. Metabolism (Clinical and experimental) 17: 1122
    CrossrefPubMedGoogle Scholar
  • 25 Nestel PJ, Schreibman PH, Ahrens EH. 1973; Cholesterol metabolism in human obesity. Journal of Clinical Investigation 1973 62: 2389
    PubMedGoogle Scholar
  • 26 Olsson AG. 1975; Studies in asymptomatic hyperlipidaemia. II. Clinical findings. Acta medica Scandinavica 197: 477
    PubMedGoogle Scholar
  • 27 Ottaviani P, Mandelli I, Fontana L, Morelli R. 1965; Comportamento del fattore stabilizzante fibrinico nelle epatopatie. Progresso (il) medico, Napoli 21: 115
    PubMedGoogle Scholar
  • 28 Popescu TA, Stef C, Moraru G, Cucuianu MP. 1977; Dilute blood clot lysis time and electrophoretic lipoprotein fractions in a population sample of healthy Romanians. Atherosclerosis 27: 155
    CrossrefPubMedGoogle Scholar
  • 29 Rose HG, Juliano J. 1976; Regulation of plasma lecithin: cholesterol acyltransferase in man. I. Increased activity in primary hypertriglyceridemia. The Journal of Laboratory and Clinical Medicine 88: 29
    PubMedGoogle Scholar
  • 30 Sheltawy MJ, Miloszewski K, Losowsky MS. 1972; Factors affecting factor XIII assay by densyl-cadaverine incorporation. Thrombosis et Diathesis Haemorrhagica 28: 483
    PubMedGoogle Scholar
  • 31 Spöttl F, Holzknecht F, Braunsteiner H. 1967; Essentielle Hyperlipämie und verminderte Fibrinolyse-Aktivität. Acta Haematologica 38: 178
    CrossrefPubMedGoogle Scholar
  • 32 Spöttl F, Holzknecht F, Braunsteiner H. 1968; Inhibitors of the plasminogen activation in patients with primary “carbohydrate-induced” hypertriglyceridemia. Journal of Atheroslcerosis Research 8: 821
    PubMedGoogle Scholar
  • 33 Tyler HM. 1972; Tissue transamidases, fibrin stabilization and clot lysis. Annals of the New York Academy of Sciences 202: 273
    CrossrefPubMedGoogle Scholar
  • 34 Walls WD, Losowsky MS. 1969; Plasma fibrin stabilizing factor (FSF) in normal subjects and patients with chronic liver disease. Thrombosis et Diathesis Haemorrhagica 21: 134
    PubMedGoogle Scholar